News | May 11, 2022
Cipla posts consolidated PAT of Rs. 362.07 crore in Q4 FY2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
Subscribe To Our Newsletter & Stay Updated
